Tuberculose multirésistante : épidémiologie et facteurs de risque

Fourati, Slim; Mzid, H.; Marouane, Chema; Kammoun, S.; Messadi-Akrout, Férièle

doi:10.1016/j.pneumo.2015.03.004

Cited by 7 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…History of tobacco and alcohol was found in 40% and 61.25% of cases, respectively, in patients with resistant TPM+ in this study. According to some authors, alcohol consumption and tobacco use are risk factors for drug-resistant tuberculosis [9]. Alcohol consumption is a problem for the metabolism of anti-TB drugs.…”

Section: Discussionmentioning

confidence: 99%

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the <i>Mycobacterium tuberculosis</i> Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Rafaï,

Namzeka,

Lango-Yaya

et al. 2023

JTR

View full text Add to dashboard Cite

Microscopy-positive and drug-resistant pulmonary tuberculosis (MPT+) is one of the most feared diseases due to the cost of its management and the associated mortality. The GeneXpert, a new molecular test, is in greater demand for the diagnosis of MPT+ resistance cases. The application of GeneXpert to new cases of MPT+ is not effective in the country's TB screening centres. The objective of this study is to assess the contribution of GeneXpert to the determination of MPT+ resistance cases in Bangui. The study was crosssectional and covered the period from February to July 2022. The diagnosis of tuberculosis was first performed by microscopy with Ziehl Neelsen hot stain. The GeneXpert was then used to test for resistance in the sputum of all patients with positive microscopy. The collected data was entered into Excel 2013 and analysed with Epi Info 3.3.7. We analysed data from 755 patients, 80 of whom had resistance. The 80 patients ranged in age from 6 to 68 years (mean age = 35 years). The prevalence of resistant TB was 10.60% (80/755). Primary resistance accounted for 73.75% and secondary resistance for 26.25%. The age group 20 -39 years (57.50%), male (72.50%), 8th district (17.50%), people living in couples (53.75%), farmers (13.75%

show abstract

Section: Discussionmentioning

confidence: 99%

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the <i>Mycobacterium tuberculosis</i> Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Rafaï,

Namzeka,

Lango-Yaya

et al. 2023

JTR

View full text Add to dashboard Cite

show abstract

“…The treatment used in TB is cumbersome, requiring the administration of several potentially toxic antibiotics over a period of several months, which has led to the emergence of drug-resistant strains of M. tb [4,5]. These strains are resistant, multidrug resistant (MDR-TB) or even extensively resistant (XDR-TB) to anti-tuberculosis drugs with an incidence that is continuously increasing.…”

Section: Introductionmentioning

confidence: 99%

Mycobacterium tuberculosis-THP-1 like macrophages protein-protein interaction map revealed through dual RNA-seq analysis and a computational approach

Hkimi,

Kamoun,

Khamessi

et al. 2024

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Infection caused by Mycobacterium tuberculosis (M. tb) is still a leading cause of mortality worldwide with estimated 1.4 million deaths annually. Hypothesis/Gap statement. Despite macrophages' ability to kill bacterium, M. tb can grow inside these innate immune cells and the exploration of the infection has traditionally been characterized by a one-sided relationship, concentrating solely on the host or examining the pathogen in isolation. Aim. Because of only a handful of M. tb–host interactions have been experimentally characterized, our main goal is to predict protein–protein interactions during the early phases of the infection. Methodology. In this work, we performed an integrative computational approach that exploits differentially expressed genes obtained from Dual RNA-seq analysis combined with known domain–domain interactions. Results. A total of 2381 and 7214 genes were identified as differentially expressed in M. tb and in THP-1-like macrophages, respectively, revealing different transcriptional profiles in response to infection. Over 48 h of infection, the host–pathogen network revealed 25 016 PPIs. Analysis of the resulting predicted network based on cellular localization information of M. tb proteins, indicated the implication of interacting nodes including the bacterial PE/PPE/PE_PGRS family. In addition, M. tb proteins interacted with host proteins involved in NF-kB signalling pathway as well as interfering with the host apoptosis ability via the potential interaction of M. tb TB16.3 with human TAB1 and M. tb GroEL2 with host protein kinase C delta, respectively. Conclusion. The prediction of the full range of interactions between M. tb and host will contribute to better understanding of the pathogenesis of this bacterium and may provide advanced approaches to explore new therapeutic targets against tuberculosis.

show abstract

“…Failure or poor adherence during drug-susceptible TB treatment increases the risk of developing MDR or XDR strains, leading to more expensive, lengthier and uncomfortable treatment for patients. 2 3 Failure and loss to follow up (LTFU) are significant factors contributing to unsuccessful TB treatment, accounting for 10%–17% of drug-susceptible TB cases and 38% of MDR TB cases. 4 5 These outcomes have been associated with lower education levels, treatment for MDR TB, and comorbid depressive and substance use disorders.…”

Section: Introductionmentioning

confidence: 99%

Are trajectories of depressive symptoms during the first half of drug-sensitive pulmonary tuberculosis treatment associated with loss to follow-up? A secondary analysis of longitudinal data

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to identify trajectories of depressive symptoms (DSs) during the first half of drug-sensitive pulmonary tuberculosis (PTB) treatment and examine their association with loss to follow-up (LTFU) in the second half.DesignThis study involved a secondary analysis of longitudinal data to identify potential trajectories of DS and their relationship with LTFU.SettingThe study was conducted in first and second-level health centres located in San Juan de Lurigancho, Lima, Peru.ParticipantsAnonymised data from 265 individuals, including monthly measures of DSs from diagnosis to the completion of treatment, initiation of treatment for multidrug resistant TB, LTFU or death, were collected.ResultsThree trajectories were identified: ‘declining’, ‘growth’ and ‘high’. These trajectories were observed in 182 (68.7%), 53 (20%) and 30 (11.3%) of the 265 individuals, respectively, during the first half of PTB treatment. Compared with those with a ‘declining’ trajectory, individuals with a ‘growth’ trajectory had a higher likelihood of experiencing LTFU during the second half of PTB treatment, after controlling for sociodemographic factors and at least weekly alcohol use (OR 3.9; 95% CI 1.09 to 13.97, p=0.036).ConclusionsThe findings suggest that a trajectory of increasing DSs during the first half of PTB treatment is associated with a higher risk of LTFU during the second half.

show abstract

Tuberculose multirésistante : épidémiologie et facteurs de risque

Cited by 7 publications

References 31 publications

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the <i>Mycobacterium tuberculosis</i> Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the <i>Mycobacterium tuberculosis</i> Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Mycobacterium tuberculosis-THP-1 like macrophages protein-protein interaction map revealed through dual RNA-seq analysis and a computational approach

Are trajectories of depressive symptoms during the first half of drug-sensitive pulmonary tuberculosis treatment associated with loss to follow-up? A secondary analysis of longitudinal data

Contact Info

Product

Resources

About

Tuberculose multirésistante : épidémiologie et facteurs de risque

Cited by 7 publications

References 31 publications

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Mycobacterium tuberculosis-THP-1 like macrophages protein-protein interaction map revealed through dual RNA-seq analysis and a computational approach

Are trajectories of depressive symptoms during the first half of drug-sensitive pulmonary tuberculosis treatment associated with loss to follow-up? A secondary analysis of longitudinal data

Contact Info

Product

Resources

About

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the <i>Mycobacterium tuberculosis</i> Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin

Contribution to the Study of Resistance to Anti-Tuberculosis Drugs in the <i>Mycobacterium tuberculosis</i> Complex Isolated at the National Laboratory of Clinical Biology and Public Health in Bangui in the Central African Republic in 2022: Case of Rifampicin